We are live on ! Find out more
ANIK icon

Anika Therapeutics

136 hedge funds and large institutions have $401M invested in Anika Therapeutics in 2015 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 56 increasing their positions, 42 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more call options, than puts

Call options by funds: $2.69M | Put options by funds: $1.76M

33% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 42

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

14% less funds holding

Funds holding: 159136 (-23)

21% less capital invested

Capital invested by funds: $505M → $401M (-$104M)

63% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 35

Holders
136
Holders Change
-23
Holders Change %
-14.47%
% of All Funds
3.65%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
13
Increased
56
Reduced
42
Closed
35
Calls
$2.69M
Puts
$1.76M
Net Calls
+$934K
Net Calls Change
-$204K

ANIK Hedge Fund Activity: Q2 2015 in Review

136 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q2 2015, worth a combined $401M — down 21% from $505M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of ANIK and 13 opened new positions — a net loss of 22 holders — while 42 trimmed existing stakes and 56 added.

The largest buyer was Thompson Siegel & Walmsley, adding an estimated $13.1M. The largest seller was Ranger Investment Management, exiting entirely with an estimated $17M sold.

  • 136 institutional investors held Anika Therapeutics (ANIK) as of Q2 2015, down from 159 in Q1 2015.
  • Funds reported $401M of Anika Therapeutics stock for Q2 2015, down 21% quarter-over-quarter.
  • 13 funds opened new Anika Therapeutics positions in Q2 2015 and 35 closed out, a net change of -22 holders.
  • The largest Anika Therapeutics buyer in Q2 2015 was Thompson Siegel & Walmsley, an estimated $13.1M added.
  • The largest Anika Therapeutics seller in Q2 2015 was Ranger Investment Management, an estimated $17M sold.

Based on aggregated 13F filings for Q2 2015.